ASAchim Schmidtko

Achim Schmidtko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Achim Schmidtko has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Gerd Geisslinger

    Pharmazentrum Frankfurt/Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit, Institut für Klinische Pharmakologie, Universitätsklinikum Frankfurt, 60590 Frankfurt am Main, Germany, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, 60590 Frankfurt am Main, Germany

    7 shared publications
  • Ruirui Lu

    Institut für Pharmakologie und Toxikologie, Universität Witten/Herdecke, Zentrum für Biomedizinische Ausbildung und Forschung, 58453 Witten, Germany, Pharmazentrum Frankfurt/Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit, Institut für Klinische Pharmakologie, Universitätsklinikum Frankfurt, 60590 Frankfurt am Main, Germany

    7 shared publications
  • Wiebke Kallenborn-Gerhardt

    Pharmazentrum Frankfurt/Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit, Institut für Klinische Pharmakologie, Universitätsklinikum Frankfurt, 60590 Frankfurt am Main, Germany

    6 shared publications
  • Jana E. Lorenz

    Pharmazentrum Frankfurt/ZAFES, Institut für Klinische Pharmakologie, Universitätsklinikum Frankfurt , Frankfurt am Main, Germany

    3 shared publications
  • Katharina M.J. Syhr

    Pharmazentrum Frankfurt/ZAFES, Institut für Klinische Pharmakologie, Universitätsklinikum Frankfurt, Frankfurt am Main, Germany

    3 shared publications
  • Marco Sisignano

    Department of Pharmacology, Faculty of Medicine, Institute of Clinical Pharmacology, Goethe University Frankfurt

    2 shared publications

Latest Publications

  • Open Access

    Slack Channels Expressed in Sensory Neurons Control Neuropathic Pain in Mice

    by Ruirui Lu, Anne E. Bausch, Wiebke Kallenborn-Gerhardt, Carsten Stoetzer, Natasja Debruin, Peter Ruth, Gerd Geisslinger, Andreas Leffler, Robert Lukowski, Achim Schmidtko

    Slack (Slo2.2) is a sodium-activated potassium channel that regulates neuronal firing activities and patterns. Previous studies identified Slack in sensory neurons, but its contribution to acute and chronic painin vivoremains elusive. Here we generated global and sensory neuron-specific Slack mutant mice and analyzed their behavior in various animal models of pain. Global ablation of Slack led to increased hypersensitivity in models of neuropathic pain, whereas the behavior in models of inflammatory and acute nociceptive pain was normal. Neuropathic pain behaviors were also exaggerated after ablation of Slack selectively in sensory neurons. Notably, the Slack opener loxapine ameliorated persisting neuropathic pain behaviors. In conclusion, Slack selectively controls the sensory input in neuropathic pain states, suggesting that modulating its activity might represent a novel strategy for management of neuropathic pain.


  • Nitric Oxide-Mediated Pain Processing in the Spinal Cord

    by Achim Schmidtko

    A large body of evidence indicates that nitric oxide (NO) plays an important role in the processing of persistent inflammatory and neuropathic pain in the spinal cord. Several animal studies revealed that inhibition or knockout of NO synthesis ameliorates persistent pain. However, spinal delivery of NO donors caused dual pronociceptive and antinociceptive effects, pointing to multiple downstream signaling mechanisms of NO. This review summarizes the localization and function of NO-dependent signaling mechanisms in the spinal cord, taking account of the recent progress made in this field.


  • Nox2-dependent signaling between macrophages and sensory neurons contributes to neuropathic pain hypersensitivity

    by Wiebke Kallenborn-Gerhardt, Stephan W. Hohmann, Katharina M.J. Syhr, Katrin Schröder, Marco Sisignano, Andreas Weigert, Jana E. Lorenz, Ruirui Lu, Bernhard Brüne, Ralf P. Brandes, et al.

    Emerging lines of evidence indicate that production of reactive oxygen species (ROS) at distinct sites of the nociceptive system contributes to the processing of neuropathic pain. However, the mechanisms underlying ROS production during neuropathic pain processing are not fully understood. We here detected the ROS-generating nicotinamide adenine dinucleotide phosphate oxidase isoform Nox2 in macrophages of dorsal root ganglia (DRG) in mice. In response to peripheral nerve injury, Nox2-positive macrophages were recruited to DRG, and ROS production was increased in a Nox2-dependent manner. Nox2-deficient mice displayed reduced neuropathic pain behavior after peripheral nerve injury, whereas their immediate responses to noxious stimuli were normal. Moreover, injury-induced upregulation of tumor necrosis factor α was absent, and activating transcription factor 3 induction was reduced in DRG of Nox2-deficient mice, suggesting an attenuated macrophage-neuron signaling. These data suggest that Nox2-dependent ROS production in macrophages recruited to DRG contributes to neuropathic pain hypersensitivity, underlining the observation that Nox-derived ROS exert specific functions during the processing of pain.


  • Oxidant-Induced Activation of cGMP-Dependent Protein Kinase Iα Mediates Neuropathic Pain After Peripheral Nerve Injury

    by Jana E. Lorenz, Wiebke Kallenborn-Gerhardt, Ruirui Lu, Katharina M.J. Syhr, Philip Eaton, Gerd Geisslinger, Achim Schmidtko

    Aims: Emerging lines of evidence indicate that oxidants such as hydrogen peroxide exert specific signaling functions during the processing of chronic pain. However, the mechanisms by which oxidants regulate pain processing in vivo remain poorly understood. Here, we investigated whether cyclic guanosine monophosphate (cGMP)-dependent protein kinase Iα (cGKIα), which can be activated by oxidants independently of cGMP, serves as a primary redox target during pain processing. Results: After peripheral nerve injury, oxidant-induced cGKIα activation is increased in dorsal root ganglia of mice. Knock-in (KI) mice in which cGKIα cannot transduce oxidant signals demonstrated reduced neuropathic pain behaviors after peripheral nerve injury, and reduced pain behaviors after intrathecal delivery of oxidants. In contrast, acute nociceptive, inflammatory, and cGMP-induced pain behaviors were not impaired in these mice. Innovation: Studying cGKIα KI mice, we provide the first evidence that oxidants activate cGKIα in sensory neurons after peripheral nerve injury in vivo.Conclusion: Our results suggest that oxidant-induced activation of cGKIα specifically contributes to neuropathic pain processing, and that prevention of cGKIα redox activation could be a potential novel strategy to manage neuropathic pain. Antioxid. Redox Signal. 21, 1504–1515.


  • Lack of effect of a P2Y6 receptor antagonist on neuropathic pain behavior in mice

    by Katharina Martina Janice Syhr, Wiebke Kallenborn-Gerhardt, Ruirui Lu, Katrin Olbrich, Katja Schmitz, Julia Männich, Nerea Ferreiros-Bouzas, Gerd Geisslinger, Ellen Niederberger, Achim Schmidtko


  • Open Access

    Phosphodiesterase 2A Localized in the Spinal Cord Contributes to Inflammatory Pain Processing

    by Wiebke Kallenborn-Gerhardt, Ruirui Lu, Aaron Bothe, Dominique Thomas, Jessica Schlaudraff, Jana E. Lorenz, Nancy Lippold, Catherine I. Real, Nerea Ferreirós, Gerd Geisslinger, et al.

    Background: Phosphodiesterase 2A (PDE2A) is an evolutionarily conserved enzyme that catalyzes the degradation of the cyclic nucleotides, cyclic adenosine monophosphate, and/or cyclic guanosine monophosphate. Recent studies reported the expression of PDE2A in the dorsal horn of the spinal cord, pointing to a potential contribution to the processing of pain. However, the functions of PDE2A in spinal pain processing in vivo remained elusive. Methods: Immunohistochemistry, laser microdissection, and quantitative real-time reverse transcription polymerase chain reaction experiments were performed to characterize the localization and regulation of PDE2A protein and messenger RNA in the mouse spinal cord. Effects of the selective PDE2A inhibitor, BAY 60–7550 (Cayman Chemical, Ann Arbor, MI), in animal models of inflammatory pain (n = 6 to 10), neuropathic pain (n = 5 to 6), and after intrathecal injection of cyclic nucleotides (n = 6 to 8) were examined. Also, cyclic adenosine monophosphate and cyclic guanosine monophosphate levels in spinal cord tissues were measured by liquid chromatography tandem mass spectrometry. Results: The authors here demonstrate that PDE2A is distinctly expressed in neurons of the superficial dorsal horn of the spinal cord, and that its spinal expression is upregulated in response to hind paw inflammation. Administration of the selective PDE2A inhibitor, BAY 60–7550, increased the nociceptive behavior of mice in animal models of inflammatory pain. Moreover, BAY 60–7550 increased the pain hypersensitivity induced by intrathecal delivery of cyclic adenosine monophosphate, but not of cyclic guanosine monophosphate, and it increased the cyclic adenosine monophosphate levels in spinal cord tissues. Conclusion: Our findings indicate that PDE2A contributes to the processing of inflammatory pain in the spinal cord.


  • BKCa channels expressed in sensory neurons modulate inflammatory pain in mice

    by Ruirui Lu, Robert Lukowski, Matthias Sausbier, Dong Dong Zhang, Marco Sisignano, Claus-Dieter Schuh, Rohini Kuner, Peter Ruth, Gerd Geisslinger, Achim Schmidtko

    Large conductance calcium-activated potassium (BKCa) channels are important regulators of neuronal excitability. Although there is electrophysiological evidence for BKCa channel expression in sensory neurons, their in vivo functions in pain processing have not been fully defined. Using a specific antibody, we demonstrate here that BKCa channels are expressed in subpopulations of peptidergic and nonpeptidergic nociceptors. To test a functional association of BKCa channel activity in sensory neurons with particular pain modalities, we generated mice in which BKCa channels are ablated specifically from sensory neurons and analyzed their behavior in various models of pain. Mutant mice showed increased nociceptive behavior in models of persistent inflammatory pain. However, their behavior in models of neuropathic or acute nociceptive pain was normal. Moreover, systemic administration of the BKCa channel opener, NS1619, inhibited persistent inflammatory pain. Our investigations provide in vivo evidence that BKCa channels expressed in sensory neurons exert inhibitory control on sensory input in inflammatory pain states.


  • Antioxidant Activity of Sestrin 2 Controls Neuropathic Pain After Peripheral Nerve Injury

    by Wiebke Kallenborn-Gerhardt, Ruirui Lu, Katharina M.J. Syhr, Juliana Heidler, Harald von Melchner, Gerd Geisslinger, Thorsten Bangsow, Achim Schmidtko

    Aims: Neuropathic pain is a chronic debilitating disease that is often unresponsive to currently available treatments. Emerging lines of evidence indicate that reactive oxygen species (ROS) are required for the development and maintenance of neuropathic pain. However, little is known about endogenous mechanisms that neutralize the pain-relevant effects of ROS. In the present study, we tested whether the stress-responsive antioxidant protein Sestrin 2 (Sesn2) blocks the ROS-induced neuropathic pain processing in vivo. Results: We observed that Sesn2 mRNA and protein expression was up-regulated in peripheral nerves after spared nerve injury, a well-characterized model of neuropathic pain. Sesn2 knockout (Sesn2 −/− ) mice exhibited considerably increased late-phase neuropathic pain behavior, while their behavior in acute nociceptive and in inflammatory pain models remained unaffected. The exacerbated neuropathic pain behavior of Sesn2 −/− mice was associated with elevated ROS levels and an enhanced activating transcription factor 3 up-regulation in sensory neurons, and it was reversed by the ROS scavenger N-tert-Butyl-α-phenylnitrone. In contrast, administration of the ROS donor tert -butyl hydroperoxide induced a prolonged pain behavior in naive Sesn2 −/− mice. Innovation: We show that the antioxidant function of Sesn2 limits neuropathic pain processing in vivo . Conclusion: Sesn2 controls ROS-dependent neuropathic pain signaling after peripheral nerve injury and may, thus, provide a potential new target for the clinical management of chronic neuropathic pain conditions. Antioxid. Redox Signal. 19, 2013–2023.